Insights - Threshold Pharmaceuticals (THLD) announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company’s pivotal phase 3 … Continue Reading
Read NowInsights - It’s been a banner year in biotech, and one of PropThink’s top picks in 2013, Keryx Biopharmaceuticals (KERX), has outperformed significantly as one of the … Continue Reading
Read NowInsights - Endocyte (ECYT) on Monday filed to sell $60 million in common stock through an At The Market sales agreement with Cowen and Company. PropThink discussed ECYT at length here and here. … Continue Reading
Premium: Read NowInsights - AcelRx (ACRX) announced on Monday a partnership with Grunenthal GmbH for the commercialization of Zalviso, the company’s patient-controlled analgesia product, in Europe and Australia. On Thursday, AcelRx entered into … Continue Reading
Read NowInsights - Vertex Pharmaceuticals (VRTX) announced that Kalydeco, its drug for cystic fibrosis (CF), showed potential benefit in patients 18 or older, despite missing a phase 3 … Continue Reading
Read NowInsights - On the heels of dropping its bid to acquire troubled Transcept Pharmaceuticals (TSPT), Retrophin, Inc. (RTRX) announced its newest clinical development candidate on Wednesday: RE-034 … Continue Reading
Read NowInsights - Alcobra Ltd. (ADHD) announced on Monday that its proprietary non-stimulant drug candidate, Metadoxine ER (MG01CI), delivered statistically positive results in a phase 2b clinical trial in adults with … Continue Reading
Read Now
